Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study-Reference-Cited by-同舟云学术

Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study

Published:2022-01 Issue: Volume:296 Page:485-492
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Dold Markus^ORCID,Bartova Lucie^ORCID,Fugger Gernot,Mitschek Marleen MM^ORCID,Fabbri Chiara,Serretti Alessandro^ORCID,Mendlewicz Julien,Souery Daniel,Zohar Joseph,Montgomery Stuart,Kasper Siegfried

Funder

H. Lundbeck A/S

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference37 articles.

1. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? a systematic review;Adli;Eur. Arch. Psychiatry Clin. Neurosci.,2005

2. Practice guideline for the treatment of patients with major depressive disorder,2010

3. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology;Baldwin;J. Psychopharmacol.,2014

4. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care;Bandelow;Int. J. Psychiatry Clin. Pract.,2012

5. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision;Bandelow;World J. Biol. Psychiatry,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genome-wide study of half a million individuals with major depression identifies 697 independent associations, infers causal neuronal subtypes and biological targets for novel pharmacotherapies;2024-05-01

2. Vortioxetine versus SSRI/SNRI with Pregabalin Augmentation in Treatment-Resistant Burning Mouth Syndrome: A Prospective Clinical Trial;CURR NEUROPHARMACOL;2024

3. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression;Neuroscience Applied;2024

4. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder;Journal of Affective Disorders;2023-11

5. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression;2023-08-28